Literature DB >> 22071978

Therapeutics. Another tool in the BCR-ABL kit?

Sarah Seton-Rogers.   

Abstract

Entities:  

Year:  2011        PMID： 22071978     DOI： 10.1038/nrc3173

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


× No keyword cloud information.
  1 in total

1.  Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis.

Authors:  Florian Grebien; Oliver Hantschel; John Wojcik; Ines Kaupe; Boris Kovacic; Arkadiusz M Wyrzucki; Gerald D Gish; Sabine Cerny-Reiterer; Akiko Koide; Hartmut Beug; Tony Pawson; Peter Valent; Shohei Koide; Giulio Superti-Furga
Journal:  Cell       Date:  2011-10-14       Impact factor: 41.582
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.